Journal
PHARMACEUTICAL RESEARCH
Volume 29, Issue 3, Pages 837-846Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-011-0611-6
Keywords
in vivo; mesoporous silicon; peptide delivery; pharmacokinetics; PYY3-36
Funding
- Finnish Cultural Foundation
- Orion Farmos Research Foundation
- Graduate School of Pharmaceutical Research
- Academy of Finland - PEPBI consortium [117906, 118002, 217547]
- University of Eastern Finland (NAMBER consortium)
- Academy of Finland (AKA) [117906, 217547, 217547, 117906] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
To achieve sustained peptide delivery via mesoporous silicon (PSi) microparticles and to evaluate the effects of different surface chemistries on peptide YY3-36 (PYY3-36) delivery. PYY3-36 was loaded into thermally oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and undecylenic acid treated THCPSi (UnTHCPSi) microparticles with comparable porous properties. In vitro, PYY3-36 release was investigated by centrifuge. In vivo, PYY3-36 plasma concentrations were analyzed after delivery in microparticles or solution. Achieved loading degrees were high (12.2 - 16.0% w/w). PYY3-36 release was sustained from all microparticles; order of PYY3-36 release was TOPSi > THCPSi > UnTHCPSi both in vitro and in vivo. In mice, PSi microparticles achieved sustained PYY3-36 release over 4 days, whereas PYY3-36 solution was eliminated in 12 h. In vitro, only 27.7, 14.5 and 6.2% of loaded PYY3-36 was released from TOPSi, THCPSi and UnTHCPSi, respectively. Absolute PYY3-36 bioavailabilities were 98, 13, 9 and 38% when delivered subcutaneously in TOPSi, THCPSi, UnTHCPSi and solution, respectively. The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release. PSi represents a promising sustained and tailorable release system for PYY3-36.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available